Compounds > trehalosamine
Page last updated: 2024-12-08

trehalosamine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

trehalosamine: strucure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID213871
CHEBI ID32525
SCHEMBL ID206428
MeSH IDM0439428

Synonyms (13)

Synonym
glucopyranoside, alpha-d-glucopyranosyl 2-amino-2-deoxy-, alpha-d-
alpha-d-glucopyranoside, alpha-d-glucopyranosyl 2-amino-2-deoxy-
CHEBI:32525
trehalosamine
27208-79-3
2-amino-2-deoxy-alpha-d-glucopyranosyl alpha-d-glucopyranoside
glcp-(1<->1)-alpha-d-glcnp
2-trehalosamine
alpha-d-glucopyranosyl 2-amino-2-deoxy-alpha-d-glucopyranoside
SCHEMBL206428
wurcs=2.0/2,2,1/[a2122h-1a_1-5][a2122h-1a_1-5_2*n]/1-2/a1-b1
Q27114973
DTXSID201317533
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
glycosyl glycoside derivativeA disaccharide derivative that is formally obtained from a glycosyl glycoside.
amino disaccharideA disaccharide derivative that is a disaccharide having one or more substituted or unsubstituted amino groups in place of hydroxy groups at unspecified positions.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (60.00)29.6817
2010's2 (40.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.63

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.63 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.42 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.63)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (20.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other4 (80.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
trehalose
alpha,alpha-trehalose : A trehalose in which both glucose residues have alpha-configuration at the anomeric carbon.		3.8130trehaloseEscherichia coli metabolite;
geroprotector;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
sulfonyl chloride
[no description available]		3.1210sulfuryl halide
3,3'-neotrehalosadiamine
3,3'-neotrehalosadiamine: from bacterial strain K169-B91; structure given in first source. 3,3'-neotrehalosadiamine : An amino disaccharide consisting of alpha- and beta-D-kanosaminyl residues joined by a (1<->1)-linkage.		2.0210amino disaccharide;
glycosyl glycoside derivative		antimicrobial agent;
metabolite
glycosides
[no description available]		3.1210
rifampin
Rifampin: A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)		2.0210cyclic ketal;
hydrazone;
N-iminopiperazine;
N-methylpiperazine;
rifamycins;
semisynthetic derivative;
zwitterion		angiogenesis inhibitor;
antiamoebic agent;
antineoplastic agent;
antitubercular agent;
DNA synthesis inhibitor;
EC 2.7.7.6 (RNA polymerase) inhibitor;
Escherichia coli metabolite;
geroprotector;
leprostatic drug;
neuroprotective agent;
pregnane X receptor agonist;
protein synthesis inhibitor
ConditionIndicatedRelationship StrengthStudiesTrials